

**Remarks/Arguments:**

Claims 2 and 4-6 are amended to correct a typographical error and promote clarity of the claims. New claims 58-60 are added. Support for new claims 58-60 can be found, e.g., at page 17, lines 7-19 of the specification. Note that nt 244-265 of the integrin  $\beta$ 1 gene (GenBank Accession No. NM 002211.2) is located within an exon of the integrin  $\beta$ 1 gene (see Exhibit A). No new matter is introduced.

Claims 1-8, 11, 19, and 58-60 are pending in the application. Reexamination and reconsideration of the application, as amended, are respectfully requested.

**CLAIM REJECTIONS UNDER 35 USC § 102(e)**

Claims 1, 3, 7, 11, and 19 are rejected as being anticipated by US 2003/0084471 to Beach et al. ("Beach"). Applicants respectfully traverse.

Claims 1 and 7 are directed to an isolated RNA comprising an artificial intron RNA that is released in a cell such as a eukaryotic cell, thereby silencing the function of a target gene. On the other hand, Beach discloses methods and compositions for RNA interference through double-stranded RNA (dsRNA). Although Beach mentions that an intronic sequence can be cloned into an expression vector for producing dsRNA, it suggests nothing whatsoever about creating an artificial intron RNA that can be released in a cell, thereby silencing the function of a target gene. To the contrary, Beach teaches only naturally-occurring introns. For example, Beaches states at page 2, right column, paragraph [0020]:

[0020] Another aspect of the present invention provides a method for attenuating expression of a target gene in cultured cells, comprising introducing an expression vector having a "non-coding sequence" which, when transcribed, produces double stranded RNA (dsRNA) in the cell in an amount sufficient to attenuate expression of the target gene. The non-coding sequence may include intronic or promoter sequence of the target gene of interest, and the dsRNA comprises a

nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence of the promoter or intron of the target gene ... (Emphasis added)

Beaches also states at page 9, right column, paragraph [0115]:

[0115] As used herein, the term "gene" or "recombinant gene" refers to a nucleic acid comprising an open reading frame encoding a polypeptide of the present invention, including both exon and (optionally) intron sequences. The nucleic acid may also optionally include non-coding sequences such as promoter or enhancer sequences. A "recombinant gene" refers to nucleic acid encoding such regulatory polypeptides, that may optionally include intron sequences that are derived from chromosomal DNA. The term "intron" refers to a DNA sequence present in a given gene that is not translated into protein and is generally found between exons. (Emphasis added)

Since Beach fails to teach an artificial RNA required by claims 1 and 7, it cannot anticipate claim 1 or 7. Claims 3, 11, and 19, dependent from claim 1, are also novel over Beach for at least the same reasons. Withdrawal of the rejections is thus respectfully requested.

#### CLAIM REJECTIONS UNDER 35 USC § 103(a)

Claims 1-8, 11, and 19 are rejected as being unpatentable over Beach in view of US 6,013,487 to Mitchell ("Mitchell"), Krawczak et al. (1992) Hum Genet 90:41-54 ("Krawczak"), Zhuang et al. (1989) PNAS 86:2752-2756 ("Zhuang"), and Coolidge et al. (1997) Nucleic Acids Research 25:888-896 ("Coolidge"). Applicants respectfully traverse.

Claims 1 and 7-8 are directed to an isolated RNA comprising an artificial intron RNA that is released in a cell such as a eukaryotic cell, thereby silencing the function of a target gene. As discussed above, Beach fails to teach such an RNA. Likewise, none of the secondary references cited by the Examiner discloses such an

RNA, and the Examiner did not rely on these references for disclosing such an RNA. Instead, the Examiner relied on the cited references for teaching a splice acceptor site (Mitchell), splice donor site (Krawczak), branch site (Zhuang), and polypyrimidine tract (Coolidge), respectively. As such, none of the secondary references can cure the defects of Beach.

Further, contrary to the Examiner's statement, one skilled in the art would not have been motivated to combine Beach and the secondary references to come up with the claimed invention. As discussed above, Beach discloses methods and compositions for RNA interference through dsRNA. Formation of such dsRNA does not depend on RNA splicing at all. See, e.g., EXAMPLE 3 at page 20, right column, paragraph [0219] – page 21, left column, paragraph [0223]; EXAMPLE 5 at page 22, right column, paragraphs [0242] – [0245]; EXAMPLE 7 at page 23, paragraphs [0251] – [0253] in Beach. Therefore, one skilled in the art would not have been motivated to modify the naturally-occurring intron sequences taught by Beach by replacing the splice acceptor sites, splice donor sites, branch sites, and polypyrimidine tracts in these introns with those taught by Mitchell, Krawczak, Zhuang, and Coolidge.

In light of the forgoing, Applicants respectfully submit that the prior art references cited by the Examiner, alone or in combination, do not render claims 1 and 7-8 obvious. Claims 2-6, 11, and 19, dependent directly or indirectly from claim 1, are also patentable over the cited art for at least the same reasons. Therefore, the rejections should be withdrawn.

### CONCLUSION

In view of the foregoing, it is respectfully submitted that the application is in condition for allowance. Reexamination and reconsideration of the application, as amended, are requested.

Appl. No. 10/663,875  
Amdt. Dated May 26, 2009  
Reply to Office Action of January 23, 2009

Attorney Docket No. 89188.0050  
Customer No.: 26021

If for any reason the Examiner finds the application other than in condition for allowance, the Examiner is requested to call the undersigned attorney at the Los Angeles, California telephone number (310) 785-4600 to discuss the steps necessary for placing the application in condition for allowance.

If there are any fees due in connection with the filing of this response, please charge the fees to our Deposit Account No. 50-1314.




Respectfully submitted,  
HOGAN & HARTSON L.L.P.

Date: May 26, 2009

By: /yjluo/  
Y. Jenny Luo, Ph.D.  
Registration No. 54,284  
Attorney for Applicants

1999 Avenue of the Stars, Suite 1400  
Los Angeles, California 90067  
Phone: 310-785-4600  
Fax: 310-785-4601

# **Exhibit A**



All DatabasesPubMedNucleotideProteinGenomeStructurePMCTaxonomyBooks

Search Nucleotide for

GoClear

My NCBI [2]  
[Sign In] [Register]

[Limits](#) [Preview/Index](#) [History](#) [Clipboard](#) [Details](#)Format: [GenBank](#) [FASTA](#) [Graphics](#) [More Formats ▼](#)[Download ▼](#) [Save ▼](#)

NCBI Reference Sequence: NM\_002211.2

**gi|19743812|ref|NM\_002211.2|**This record has been replaced by [NM\\_002211.3](#)[Comment](#) [Features](#) [Sequence](#)

LOCUS NM\_002211 3700 bp mRNA  
linear PRI 16-MAR-2008  
DEFINITION Homo sapiens integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12) (ITGB1), transcript variant 1A, mRNA.  
ACCESSION NM\_002211  
VERSION NM\_002211.2 GI:19743812  
KEYWORDS .  
SOURCE Homo sapiens (human)  
ORGANISM [Homo sapiens](#)  
Eukaryota; Metazoa; Chordata; Craniata;  
Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Euarchontoglires; Primates;  
Haplorrhini;  
Catarrhini; Hominidae; Homo.  
REFERENCE 1 (bases 1 to 3700)  
AUTHORS Bhoopathi,P., Chetty,C., Kunigal,S.,  
Vanamala,S.K., Rao,J.S. and  
Lakka,S.S.  
TITLE Blockade of tumor growth due to matrix metalloproteinase-9 inhibition is mediated by sequential activation of betal-integrin, ERK, and NF-kappaB  
JOURNAL J. Biol. Chem. 283 (3), 1545-1552 (2008)  
PUBMED [17991734](#)  
REMARK GeneRIF: These results indicate that MMP-9 inhibition induces apoptosis due to altered betal-integrin expression in medulloblastoma and ERK activation plays an active role and functions upstream of NF-kappaB activation to initiate the apoptotic signal.  
REFERENCE 2 (bases 1 to 3700)  
AUTHORS Saidi,S., Mahjoub,T., Slamia,L.B., Ammou,S.B., Al-Subaie,A.M. and

[Change Region Shown](#)[Customize View](#)**Sequence Analysis Tools****[BLAST Sequence](#)**

Find regions of similarity between this sequence and other sequences using BLAST.

**[Pick Primers](#)**

Design and test primers for this sequence using Primer-BLAST.

**Recent Activity**[Turn Off](#) [Clear](#)

gi|19743812|ref|NM\_00

Almawi,W.Y.  
 TITLE Association of human platelet alloantigen 1  
 through 5 polymorphisms  
 with ischemic stroke  
 JOURNAL Cerebrovasc. Dis. 25 (1-2), 81-86 (2008)  
 PUBMED [18057877](#)  
 REMARK GeneRIF: Observational study of gene-disease  
 association. (HuGENet)  
 REFERENCE 3 (bases 1 to 3700)  
 AUTHORS Bolduc,G.R. and Madoff,L.C.  
 TITLE The group B streptococcal alpha C protein binds  
 alphabeta1-integrin through a novel KTD motif  
 that promotes  
 internalization of GBS within human epithelial  
 cells  
 JOURNAL Microbiology (Reading, Engl.) 153 (PT 12), 4039-  
 4049 (2007)  
 PUBMED [18048918](#)  
 REMARK GeneRIF: Group B streptococci ACP binds alpha(1)  
 beta(1)-integrin  
 via the D1 domain that promotes GBS  
 internalization within  
 epithelial cells.  
 REFERENCE 4 (bases 1 to 3700)  
 AUTHORS Hu,K., Wu,C., Mars,W.M. and Liu,Y.  
 TITLE Tissue-type plasminogen activator promotes  
 murine myofibroblast  
 activation through LDL receptor-related protein  
 1-mediated integrin  
 signaling  
 JOURNAL J. Clin. Invest. 117 (12), 3821-3832 (2007)  
 PUBMED [18037995](#)  
 REMARK GeneRIF: tPA induces LRP-1 tyrosine  
 phosphorylation, which in turn  
 facilitates the LRP-1-mediated recruitment of  
 beta1 integrin and  
 downstream ILK signaling, thereby leading to  
 myofibroblast  
 activation.  
 REFERENCE 5 (bases 1 to 3700)  
 AUTHORS Yao,K., Tan,J., Ye,P., Wang,K., Xu,W., ShenTu,X.  
 and Tang,X.  
 TITLE Integrin beta1-mediated signaling is involved in  
 transforming  
 growth factor-beta2-promoted migration in human  
 lens epithelial  
 cells  
 JOURNAL Mol. Vis. 13, 1769-1776 (2007)  
 PUBMED [17960115](#)  
 REMARK GeneRIF: TGF-beta2 promoted human lens  
 epithelial cell adhesion and  
 migration in vitro. Integrin beta1 and integrin-  
 mediated signaling  
 are necessary for TGF-beta2-promoted adhesion  
 and migration in  
 human lens epithelial cells.  
 Publication Status: Online-Only  
 REFERENCE 6 (bases 1 to 3700)  
 AUTHORS Languino,L.R. and Ruoslahti,E.  
 TITLE An alternative form of the integrin beta 1  
 subunit with a variant  
 cytoplasmic domain

JOURNAL J. Biol. Chem. 267 (10), 7116-7120 (1992)  
 PUBMED [1551917](#)  
 REFERENCE 7 (bases 1 to 3700)  
 AUTHORS Otey,C.A., Pavalko,F.M. and Burridge,K.  
 TITLE An interaction between alpha-actinin and the beta 1 integrin subunit in vitro

JOURNAL J. Cell Biol. 111 (2), 721-729 (1990)  
 PUBMED [2116421](#)  
 REFERENCE 8 (bases 1 to 3700)  
 AUTHORS Sonnenberg,A., Linders,C.J., Modderman,P.W., Damsky,C.H., Aumailley,M. and Timpl,R.  
 TITLE Integrin recognition of different cell-binding fragments of laminin (P1, E3, E8) and evidence that alpha 6 beta 1 but not alpha 6 beta 4 functions as a major receptor for fragment E8

JOURNAL J. Cell Biol. 110 (6), 2145-2155 (1990)  
 PUBMED [1693624](#)  
 REFERENCE 9 (bases 1 to 3700)  
 AUTHORS Vogel,B.E., Tarone,G., Giancotti,F.G., Gailit,J. and Ruoslahti,E.  
 TITLE A novel fibronectin receptor with an unexpected subunit composition (alpha v beta 1)

JOURNAL J. Biol. Chem. 265 (11), 5934-5937 (1990)  
 PUBMED [2138612](#)  
 REFERENCE 10 (bases 1 to 3700)  
 AUTHORS Bodary,S.C. and McLean,J.W.  
 TITLE The integrin beta 1 subunit associates with the vitronectin receptor alpha v subunit to form a novel vitronectin receptor in a human embryonic kidney cell line

JOURNAL J. Biol. Chem. 265 (11), 5938-5941 (1990)  
 PUBMED [1690718](#)  
 COMMENT REVIEWED [REFSEQ](#): This record has been curated by NCBI staff. The reference sequence was derived from [X07979.1](#), [BC020057.1](#) and [X68969.1](#).  
 [WARNING] On Apr 11, 2008 this sequence was replaced by [gi:162519230](#).  
 On Mar 26, 2002 this sequence version replaced [gi:4504766](#).

Summary: Integrins are heterodimeric proteins made up of alpha and beta subunits. At least 18 alpha and 8 beta subunits have been described in mammals. Integrin family members are membrane receptors involved in cell adhesion and recognition in a variety of processes including embryogenesis, hemostasis, tissue repair, immune response and metastatic diffusion of tumor cells. The protein encoded by this gene is a beta subunit. Six alternatively spliced variants have been found for this gene which encode five proteins with alternate carboxy termini.

Transcript Variant: This variant (1A) is the most common variant and has an alternate 5'UTR due to the use of the alternate proximal promoter. Variants 1A and 1E encode the same isoform.

Publication Note: This RefSeq record includes a subset of the publications that are available for this gene. Please see the Entrez Gene record to access additional publications.

COMPLETENESS: full length.

FEATURES  
 source Location/Qualifiers  
 1..3700  
 /organism="Homo sapiens"  
 /mol\_type="mRNA"  
 /db\_xref="taxon:[9606](#)"  
 /chromosome="10"  
 /map="10p11.2"  
 gene 1..3700



```

/ gene="ITGB1"
/ gene_synonym="CD29; FNRB; GPIIA; MDF2; MSK12; VLAB"
/ note="integrin, beta 1 (fibronectin receptor, beta
polypeptide, antigen CD29 includes MDF2, MSK12)"
/ db_xref="GeneID:3688"
/ db_xref="HGNC:6153"
/ db_xref="HPRD:00628"
/ db_xref="MIM:135630"
exon
1..126
/ gene="ITGB1"
/ gene_synonym="CD29; FNRB; GPIIA; MDF2; MSK12; VLAB"
/ inference="alignment:Splign"
/ number=1
misc_feature
1
/ gene="ITGB1"
/ gene_synonym="CD29; FNRB; GPIIA; MDF2; MSK12; VLAB"
/ note="5' most of multiple alternative transcription
initiation sites"
CDS
127..2523
/ gene="ITGB1"
/ gene_synonym="CD29; FNRB; GPIIA; MDF2; MSK12; VLAB"
/ note="isoform 1A precursor is encoded by transcript
variant 1A; integrin VLA-4 beta subunit; fibronectin
receptor beta subunit"
/ codon_start=1
/ product="integrin beta 1 isoform 1A precursor"
/ protein_id="NP_002202.2"
/ db_xref="GI:19743813"
/ db_xref="CCDS:CCDS7174.1"
/ db_xref="GeneID:3688"
/ db_xref="HGNC:6153"
/ db_xref="HPRD:00628"
/ db_xref="MIM:135630"
/ translation="MNLQPIFWIGLISSVCCVFAQTDENRCLKANAKSCGECIQAGPN
CGWCTNSTFLQEGMPTSARCDDLEALKKKGCPDDIENPRGSKDIKKNKNTNRSGKT
AEKLPEDITQIQPQQLVLRRLRSGEPQFTLKFKAEDYPIDLYLMDLSYMKDDLE
NVKSLGTDLMNEMRRITSDFRIGFGSFVEKTVMPYISTTPAKLRNPCTSEQNCTSPFS
YKNVLSLTNKGEVFNELVGKQRI SGNLDSPGGFDAIMQVAVCGSLIGWRNVTRLLVF
STDAGFHFAGDGKLGIVLPNDGQCHLENNMYTMSHYDYPSIAHLVQKLSENNQITI
FAVTEEFQPVYKELKNLIPKSAVGTLSSANSNVIQLIIDAYNSLSSEVILENGKLSEG
VTISYKSYCKNGVNGTGENGRKCSNISIGDEVQFEISITSNKC PKKDSDSFKIRPLGF
TEEVEVILQYICECECQSEGIPE SPKCHEGNGTFECGACRCNEGRVGRHCECSTDEVN
SEMDAYCRKENSSEICSNNGECVCGQCVCRRKRDNTNEIYSGKFCECDNFNCDRSNGL
ICGGNGVCKCRVCECNPNYTGSA CDCLDTSTCEASNGQICNGRGICEGVCCKTDPK
FQGQTC EMCQTC LGVCAEHKECVQCRAF NKGEKKDTCTQECSYFNITKVESRD KLPQP
VQPD PVSHCKEKDVDDCW FYFTYSVNGNNEVMVHVVENPECPTGPDIIPIVAGVVAGI
VLIGLALLLIWKLLMIIHDRREFAKFEKEKMNAKWD TGENPIYKSAVTTVVNPKYEGK"
sig_peptide
127..186
/ gene="ITGB1"
/ gene_synonym="CD29; FNRB; GPIIA; MDF2; MSK12; VLAB"
mat_peptide
187..2520
/ gene="ITGB1"
/ gene_synonym="CD29; FNRB; GPIIA; MDF2; MSK12; VLAB"
/ product="integrin beta 1 isoform 1A"
exon
127..193
/ gene="ITGB1"
/ gene_synonym="CD29; FNRB; GPIIA; MDF2; MSK12; VLAB"
/ inference="alignment:Splign"
/ number=3
exon
194..279
/ gene="ITGB1"
/ gene_synonym="CD29; FNRB; GPIIA; MDF2; MSK12; VLAB"

```

exon /inference="alignment:Splign"  
/number=4  
280..502  
/gene="ITGB1"  
/gene\_synonym="CD29; FNRB; GPIIA; MDF2; MSK12; VLAB"  
/inference="alignment:Splign"  
/number=5  
exon 503..673  
/gene="ITGB1"  
/gene\_synonym="CD29; FNRB; GPIIA; MDF2; MSK12; VLAB"  
/inference="alignment:Splign"  
/number=6  
exon 674..912  
/gene="ITGB1"  
/gene\_synonym="CD29; FNRB; GPIIA; MDF2; MSK12; VLAB"  
/inference="alignment:Splign"  
/number=7  
exon 913..1068  
/gene="ITGB1"  
/gene\_synonym="CD29; FNRB; GPIIA; MDF2; MSK12; VLAB"  
/inference="alignment:Splign"  
/number=8  
exon 1069..1164  
/gene="ITGB1"  
/gene\_synonym="CD29; FNRB; GPIIA; MDF2; MSK12; VLAB"  
/inference="alignment:Splign"  
/number=9  
exon 1165..1254  
/gene="ITGB1"  
/gene\_synonym="CD29; FNRB; GPIIA; MDF2; MSK12; VLAB"  
/inference="alignment:Splign"  
/number=10  
exon 1255..1395  
/gene="ITGB1"  
/gene\_synonym="CD29; FNRB; GPIIA; MDF2; MSK12; VLAB"  
/inference="alignment:Splign"  
/number=11  
exon 1396..1595  
/gene="ITGB1"  
/gene\_synonym="CD29; FNRB; GPIIA; MDF2; MSK12; VLAB"  
/inference="alignment:Splign"  
/number=12  
exon 1596..1834  
/gene="ITGB1"  
/gene\_synonym="CD29; FNRB; GPIIA; MDF2; MSK12; VLAB"  
/inference="alignment:Splign"  
/number=13  
exon 1835..2057  
/gene="ITGB1"  
/gene\_synonym="CD29; FNRB; GPIIA; MDF2; MSK12; VLAB"  
/inference="alignment:Splign"  
/number=14  
exon 2058..2290  
/gene="ITGB1"  
/gene\_synonym="CD29; FNRB; GPIIA; MDF2; MSK12; VLAB"  
/inference="alignment:Splign"  
/number=15  
STS 2122..2583  
/gene="ITGB1"  
/gene\_synonym="CD29; FNRB; GPIIA; MDF2; MSK12; VLAB"  
/standard\_name="PMC59887P1"  
/db\_xref="UniSTS:273375"

```

exon          2291..2457
               /gene="ITGB1"
               /gene_synonym="CD29; FNRB; GPIIA; MDF2; MSK12; VLAB"
               /inference="alignment:Splign"
               /number=16a
exon          2458..3700
               /gene="ITGB1"
               /gene_synonym="CD29; FNRB; GPIIA; MDF2; MSK12; VLAB"
               /inference="alignment:Splign"
               /number=19c
STS          2533..2794
               /gene="ITGB1"
               /gene_synonym="CD29; FNRB; GPIIA; MDF2; MSK12; VLAB"
               /standard_name="D10S2370"
               /db_xref="UniSTS:57957"
STS          3026..3607
               /gene="ITGB1"
               /gene_synonym="CD29; FNRB; GPIIA; MDF2; MSK12; VLAB"
               /standard_name="GDB:181546"
               /db_xref="UniSTS:155272"
STS          3082..3210
               /gene="ITGB1"
               /gene_synonym="CD29; FNRB; GPIIA; MDF2; MSK12; VLAB"
               /standard_name="SHGC-32719"
               /db_xref="UniSTS:167675"
STS          3132..3322
               /gene="ITGB1"
               /gene_synonym="CD29; FNRB; GPIIA; MDF2; MSK12; VLAB"
               /standard_name="RH47140"
               /db_xref="UniSTS:89260"
STS          3292..3506
               /gene="ITGB1"
               /gene_synonym="CD29; FNRB; GPIIA; MDF2; MSK12; VLAB"
               /standard_name="RH40308"
               /db_xref="UniSTS:92921"
STS          3495..3587
               /gene="ITGB1"
               /gene_synonym="CD29; FNRB; GPIIA; MDF2; MSK12; VLAB"
               /standard_name="RH47472"
               /db_xref="UniSTS:84058"
polyA_signal 3671..3676
               /gene="ITGB1"
               /gene_synonym="CD29; FNRB; GPIIA; MDF2; MSK12; VLAB"
polyA_site    3699
               /gene="ITGB1"
               /gene_synonym="CD29; FNRB; GPIIA; MDF2; MSK12; VLAB"
ORIGIN
      1 agccgcccgcg acccgcccgcg cccgacaccc gggaggcccc gccagcccgc gggagaggcc
     61 cagcgggagtg cgcggaacag caggcccgcg cccaccgcgc cgggcccccg acgcccgcgc
    121 gaaaagatga atttacaacc aattttctgg attggactga tcagttcagt ttgctgtgtg
    181 tttgctcaaa cagatgaaaa tagatgttta aaagcaaagt ccaaatacatg tggagaatgt
    241 atacaagcag ggccaaattg tgggtggtgc acaaattcaa catttttaca ggaaggaatg
    301 cctacttctg cacgatgtga tgatttagaa gccttaaaaa agaagggttg cctccagat
    361 gacatagaaa atcccagagg ctccaaagat ataaagaaaa ataaaaatgt aaccaaccgt
    421 agcaaaggaa cagcagagaa gctcaagcca gaggatatta ctcagatcca accacagcag
    481 ttggttttgc gattaagatc aggggagcca cagacattta cattaaaatt caagagagct
    541 gaagactatc ccattgacct ctactacctt atggacctgt cttactcaat gaaagacgat
    601 ttggagaatg taaaaagtct tggaacagat ctgatgaatg aaatgaggag gattacttcg
    661 gacttcagaa ttggatttgg ctcatattgtg gaaaagactg tgatgcctta cattagcaca
    721 acaccagcta agctcaggaa cccttgacac agtgaacaga actgcaccag cccatttagc
    781 tacaaaaatg tgctcagtct tactaataaa ggagaagtat ttaatgaact tgttggaata
    841 cagcgcataat ctggaaattt ggattctcca gaagtggtt tcgatgccat catgcaagtt

```

901 gcagtttgtg gatcactgat tggctggagg aatgttacac ggctgctggt gttttccaca  
961 gatgccgggt ttcactttgc tggagatggg aaacttggtg gcattgtttt accaaatgat  
1021 ggacaatgtc acctggaaaa taatatgtac acaatgagcc attattatga ttatccttct  
1081 attgctcacc ttgtccagaa actgagtga aataatattc agacaatttt tgcagttact  
1141 gaagaatttc agcctgttta caaggagctg aaaaacttga tccctaagtc agcagtagga  
1201 acattatctg caaattctag caatgtaatt cagttgatca ttgatgcata caattccctt  
1261 tcctcagaag tcatttttga aaacggcaaa ttgtcagaag gagtaacaat aagttacaaa  
1321 tcttactgca agaacgggggt gaatggaaca ggggaaaatg gaagaaaatg ttccaatatt  
1381 tccattggag atgaggttca atttgaaatt agcataactt caaataagtg tccaaaaaag  
1441 gattctgaca gctttaaaaat taggcctctg ggctttacgg aggaagtaga ggttattcct  
1501 cagtacatct gtgaatgtga atgccaaagc gaaggcatcc ctgaaagtcc caagtgtcat  
1561 gaaggaaatg ggacatttga gtgtggcgcg tgcaggtgca atgaaggcg tgttggtaga  
1621 cattgtgaat gcagcacaga tgaagttaac agtgaagaca tggatgctta ctgcaggaaa  
1681 gaaaacagtt cagaaatctg cagtaacaat ggagagtgcg tctgcggaca gtgtgtttgt  
1741 aggaagaggg ataatacaaa tgaaatttat tctggcaaat tctgcgagtg tgataatttc  
1801 aactgtgata gatccaatgg cttaatttct ggaggaaatg gtgtttgcaa gtgtcgtgtg  
1861 tgtgagtgc aacccaacta cactggcagt gcatgtgact gttcttttga tactagtact  
1921 tgtgaagcca gcaacggaca gatctgcaat ggccggggca tctgcgagtg tgggtgtctgt  
1981 aagtgtacag atccgaagtt tcaagggcaa acgtgtgaga tgtgtcagac ctgccttggg  
2041 gtctgtgctg agcataaaga atgtgttcag tgcagagcct tcaataaagg agaaaagaaa  
2101 gacacatgca cacaggaatg ttcctatttt aacattacca aggtagaaag tccggacaaa  
2161 ttaccccagc cgggtccaacc tgatcctgtg tccatttga aggagaagg tggtgacgac  
2221 tgttggttct attttacgta ttcagtgaat gggaacaacg aggtcatggg tcatgttgtg  
2281 gagaatccag agtgtccac tgggtccagac atcattccaa ttgtagctgg tgtggttgc  
2341 ggaattgttc ttattggcct tgcattactg ctgatatgga agcttttaat gataattcat  
2401 gacagaaggg agtttgctaa atttgaaaag gagaaaatga atgccaaatg ggacacgggt  
2461 gaaaatccta ttataagag tgccgtaaca actgtggtca atccgaagta tgagggaaaa  
2521 tgagtactgc ccgtgcaaat ccacacaac tgaatgcaaa gtagcaattt ccatagtcac  
2581 agttaggtag ctttagggca atattggcat ggttttactc atgtgcaggt tttgaaaatg  
2641 tacaatatgt ataattttta aaatgtttta ttattttgaa aataatgttg taattcatgc  
2701 cagggactga caaaagactt gagacaggat gggtattcct gtcagctaag gtcacattgt  
2761 gcctttttga ctttttcttc ctggactatt gaaatcaagc ttattggatt aagtgatatt  
2821 tctatagcga ttgaaagggc aatagttaaa gtaatgagca tgatgagagt ttctgttaat  
2881 catgtattaa aactgatttt tagctttaca aatatgtcag tttgcagtta tgcagaatcc  
2941 aaagtaaatg tcctgctagc tagttaagga ttgttttaaa tctgttattt tgctatttgc  
3001 ctgttagaca tgactgatga catatctgaa agacaagtat gttgagagtt gctgggtgaa  
3061 aatcgttttg aaatagttga tctacaaagg ccatgggaaa aattcagaga gttaggaagg  
3121 aaaaaccaat agcttttaaaa cctgtgtgcc attttaagag ttacttaatg ttttctgcta  
3181 tttatgcctt cacttttaca attcaagcct tagataaaaag aaccgagcaa ttttctgcta  
3241 aaaagtcctt gatttagcac tatttacata caggccatac tttacaaagt atttgctgaa  
3301 tggggacctt ttgagttgaa tttattttat tatttttatt ttgtttaatg tctggtgctt  
3361 tctatcacct cttctaactt tttaatgtat ttgtttgcaa ttttggggta agactttttt  
3421 atgagtactt tttctttgaa gtttttagcg tcaatttgcc tttttaatga acatgtgaag  
3481 ttatactgtg gctatgcaac agctctcacc tacgcgagtc ttacttttag ttagtgccat  
3541 aacagaccac tgtatgttta cttctcacca tttgagttgc ccactctgtt tcacactagt  
3601 cacattcttg ttttaagtg ctttagtttt aacagttcac tttttacagt gctatttact  
3661 gaagttattt attaaatatg cctaaaatac ttaaatcgga

//

[Write to the Help Desk](#)[NCBI](#) | [NLM](#) | [NIH](#)[Department of Health & Human Services](#)[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)